In a reversal of fortunes, a federal judge overturned a jury verdict ordering Gilead Sciences (GILD) to pay $2.54 billion to Merck (MRK) for infringing a patent in order to develop a pair of blockbuster hepatitis C treatments. Continue reading “A reversal of fortunes: Judge voids order Gilead must pay $2.5B to Merck over a patent dispute”